Compare Johnson Controls International PLC (JCI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs TG Therapeutics Inc — how do they compare? Johnson Controls International PLC trades at $157.44 (market cap $93.28B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Johnson Controls International PLC is far larger — about 11.4× TG Therapeutics Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and TG Therapeutics Inc for 16 Days on average.
| JCI | TGTX | |
|---|---|---|
Market Cap | $93.28B | $8.16B |
Volume | 2,786,476 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $59.06 |
52-Week Low | $105.55 | $26.94 |
Typical Hold Time | 65 Days | 16 Days |
Enterprise Value | $102.12B | $8.37B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $157.44, up 0.97% on the day, reflecting strong momentum after beating earnings estimates for three consecutive quarters. The stock exhibits a bullish technical outlook, trading above key support levels, while fundamentals are supported by a 13.94% net income margin and robust ROE of 24.42%. Recent news highlights inclusion in AI industrial stock recommendations and strong Q3 2026 results with raised full-year guidance.
The outlook for JCI remains positive, driven by earnings outperformance and strong demand in thermal management and building systems. Key opportunities include expanding margins and strategic positioning in energy efficiency markets. Risks involve elevated valuation multiples and increasing debt-to-asset ratios, which could pressure the stock if growth moderates.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
